Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...

SAN FRANCISCO--(BUSINESS WIRE)--Vector Capital (“Vector”), a leading private equity firm specializing in transformational investments in established technology businesses, today announced it has ...

MILWAUKEE, Jan. 8, 2026 /PRNewswire/ -- Vector Technologies, a leader in industrial and hydro excavation vacuum systems, proudly celebrates its 50th anniversary in 2026. Since its founding in 1976, ...

TORONTO, Jan. 22, 2026 /CNW/ - Agentiiv – a pioneer in enterprise-grade, agentic AI systems in Canada – today announced a technology partnership with the Vector Institute. As a Vector technology ...

Introgen Therapeutic’s (Austin, TX) p53-based INGN 225 cancer vaccine yielded promising safety and efficacy results in a Phase II trial in advanced small cell lung cancer. The personalized therapeutic ...

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...

Based in San Francisco, Vector Capital invests in middle-market technology and technology-enabled businesses Vector was founded in 1997 Vector Capital has agreed to acquire San Francisco-based ...